irinotecan liposome + apatinib + camrelizumab

irinotecan liposome + apatinib + camrelizumab is an investigational combination therapeutic regimen being evaluated by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School for the treatment of advanced solid tumors. The regimen integrates three distinct therapeutic modalities: chemotherapy via a liposomal formulation of irinotecan (a topoisomerase I inhibitor), anti-angiogenic therapy with apatinib (a selective VEGFR-2 tyrosine kinase inhibitor), and immunotherapy with camrelizumab (an anti-PD-1 monoclonal antibody). In clinical trials, this combination is typically administered following stereotactic body radiotherapy (SBRT) to exploit potential synergistic effects, such as the abscopal effect and enhanced drug delivery through vascular normalization. The treatment is aimed at patients who have progressed on or are ineligible for standard-of-care therapies across various solid tumor types, including gastrointestinal and lung cancers.

Other names

Radiotherapy + irinotecan liposome + apatinib + camrelizumabIrinotecan liposome + apatinib + camrelizumab